Eli Lilly & Co.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5324571083
USD
1,001.35
-7.04 (-0.7%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Eli Lilly & Co.
Vertex Pharmaceuticals, Inc.
Bristol Myers Squibb Co.
Regeneron Pharmaceuticals, Inc.
Zoetis, Inc.
Johnson & Johnson
Merck & Co., Inc.
Pfizer Inc.
AbbVie, Inc.
Seagen Inc.
Horizon Therapeutics Plc

Why is Eli Lilly & Co. ?

1
High Management Efficiency with a high ROCE of 33.55%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 21.74
3
Healthy long term growth as Net Sales has grown by an annual rate of 18.34%
4
With a growth in Net Profit of 105.14%, the company declared Very Positive results in Jun 25
  • The company has declared positive results for the last 4 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 10,938.2 MM
  • ROCE(HY) Highest at 86.7%
  • DIVIDEND PER SHARE(HY) Highest at USD 3.52
5
With ROCE of 38.63%, it has a expensive valuation with a 14.99 Enterprise value to Capital Employed
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 26.80%, its profits have risen by 54.2% ; the PEG ratio of the company is 0.9
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Eli Lilly & Co. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Eli Lilly & Co. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Eli Lilly & Co.
20.68%
0.41
40.64%
S&P 500
20.78%
0.70
20.15%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
21.58%
EBIT Growth (5y)
34.09%
EBIT to Interest (avg)
21.74
Debt to EBITDA (avg)
1.64
Net Debt to Equity (avg)
2.24
Sales to Capital Employed (avg)
0.93
Tax Ratio
18.34%
Dividend Payout Ratio
26.14%
Pledged Shares
0
Institutional Holding
83.35%
ROCE (avg)
33.55%
ROE (avg)
83.66%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
41.92
EV to EBIT
35.76
EV to EBITDA
32.98
EV to Capital Employed
14.69
EV to Sales
15.07
PEG Ratio
0.94
Dividend Yield
0.00%
ROCE (Latest)
41.07%
ROE (Latest)
93.61%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

31What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 16,813 MM

ROCE(HY)

Highest at 101.35%

DIVIDEND PER SHARE(HY)

Highest at USD 3.9

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

RAW MATERIAL COST(Y)

Fallen by -0.34% (YoY

CASH AND EQV(HY)

Highest at USD 17,181.5 MM

DEBT-EQUITY RATIO (HY)

Lowest at 137.92 %

DEBTORS TURNOVER RATIO(HY)

Highest at 3.9 times

NET SALES(Q)

Highest at USD 19,292 MM

OPERATING PROFIT(Q)

Highest at USD 9,571.7 MM

PRE-TAX PROFIT(Q)

Highest at USD 8,898.6 MM

NET PROFIT(Q)

Highest at USD 7,144.72 MM

EPS(Q)

Highest at USD 7.02

-4What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 1.04 times

DIVIDEND PAYOUT RATIO(Y)

Lowest at 21.36%

Here's what is working for Eli Lilly & Co.

Operating Cash Flow
Highest at USD 16,813 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Dividend per share
Highest at USD 3.9 and Grown
In each year in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (USD)

Net Sales
Highest at USD 19,292 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Net Sales
At USD 19,292 MM has Grown at 29.87%
over average net sales of the previous four periods of USD 14,854.95 MM
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD 9,571.7 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD 8,898.6 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Pre-Tax Profit
At USD 8,898.6 MM has Grown at 39.16%
over average net sales of the previous four periods of USD 6,394.42 MM
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD 7,144.72 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD 7.02
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv
Highest at USD 17,181.5 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at 137.92 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 3.9 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -0.34% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 585.7 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Eli Lilly & Co.

Inventory Turnover Ratio
Lowest at 1.04 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Dividend Payout Ratio
Lowest at 21.36%
in the last five years
MOJO Watch
Company is distributing lower proportion of profits generated as dividend

DPR (%)